Significance of epidermal mitoses in challenging melanocytic proliferations

Background: Accurate diagnosis of melanoma remains histologically challenging. Dermal mitoses support malignancy, but are only occasionally seen in melanomas. As melanomagenesis is thought to begin at the dermal-epidermal junction, we investigated the significance of epidermal melanocytic mitoses (EMM) in a spectrum of lesions with molecular characterization.

Methods: Epidermal mitoses density (EMD) was evaluated in 46 straightforward lesions (24 benign and 22 malignant) and 30 challenging lesions with expert interpretation, fluorescence *in situ* hybridization and myPath-score characterization (12 favor-benign, 9 favor-malignant and 9 ambiguous). EMD was correlated with clinicopathologic parameters and myPath.

Results: In straightforward cases, 25% nevi and 77% melanomas had EM. Median EMD was significantly lower in nevi vs. melanomas ($0/mm$ vs. $0.04/mm$, $p = 0.001$). EMD ($0.01/mm$-cutoff) had 77% sensitivity, 79% specificity discriminating melanomas from nevi. In challenging cases, 17% favor-benign, 67% favor-malignant and 78% ambiguous lesions had EM. EMD ($0.01/mm$-cutoff) had 67% sensitivity, 82% specificity on 21 non-ambiguous lesions, similar to myPath. EMD was less accurate in Spitzoid lesions, which have high EMD and dermal mitoses.

Conclusion: While EMD is not an adequate single criterion in diagnosing melanoma, our results validate its discriminatory potential, suggesting that EM should prompt closer investigation for malignancy. Expanded studies with clinical follow up are warranted to further assess the EM utility in classifying melanocytic lesions.

Keywords: epidermal mitoses, junctional mitoses, melanoma, myPath

Minca EC, Billings SD, Elson P, Tetzlaff MT, Andea AA, Ko JS.
Significance of epidermal mitoses in challenging melanocytic proliferations.
J Cutan Pathol 2017; 44: 135–143. © 2016 John Wiley & Sons A/S.
Published by John Wiley & Sons Ltd

Eugen C. Minca[1,2],
Steven D. Billings[1,2],
Paul Elson[1,2,3],
Michael T. Tetzlaff[3,4],
Aleodor A. Andea[4,5] **and**
Jennifer S. Ko[1,2]

[1]Department of Pathology, Cleveland Clinic, Cleveland, OH, USA,
[2]Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA,
[3]Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA,
[4]Department of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA, and
[5]Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI, USA

Jennifer S. Ko, MD, PhD,
Department of Pathology,
Cleveland Clinic,
9500 Carnegie Avenue,
L25, Cleveland,
OH 44195, USA
Tel: +1 216 386 2877
Fax: +1 216 445 9535
e-mail: koj2@ccf.org

Melanoma is the most life threatening form of skin cancer,[1] yet it can be the most difficult to diagnose on histopathologic parameters.[2−6] There are various morphologic mimickers of melanoma including nevi with high-grade dysplasia and Spitz tumors,[7,8] and melanomas can occur in a broad age distribution.[9] Thus, there exists a group of melanocytic proliferations in which definitive classification as benign or malignant either cannot be made with certainty, or requires the use of ancillary, including molecular tests.

Criteria to distinguish melanoma have traditionally been divided into architectural and cytologic.[10] Many of the architectural criteria used to diagnose melanoma – pagetoid spread of melanocytes, lentiginous growth, bridging of rete ridge nests and misplaced/misshaped nests overlap to varying degrees with dysplastic nevi. Cytologic features used to classify melanoma such as cellular enlargement, prominent nucleoli and reduced maturation can be seen in Spitz nevi. Dermal mitotic figures are somewhat rare (0−15% based on numerous studies) in benign nevi, and when combined with other histologic features of melanoma, are quite consistent with the diagnosis.[11] This is related to the fact that most benign melanocytic lesions decrease proliferation and enter senescence once in the inhospitable environment of the dermis.[12] Nevertheless, most early melanomas do not show dermal mitotic figures, hence this criterion may be of no aid in the discrimination of thin or borderline melanocytic proliferations.

Melanomagenesis takes place at the dermal-epidermal junction,[12] and yet the significance of epidermal mitotic figures in challenging melanocytic proliferations has not been systematically evaluated. Here, we have assessed and quantified epidermal melanocytic mitoses in a cohort of histologically straightforward, and histologically difficult melanocytic lesions with molecular characterization [myPath gene expression score (Myriad Genetics, Salt Lake City, UT, USA) and fluorescence *in situ* hybridization (FISH)] and expert consensus diagnosis. The presence and density of epidermal melanocytic mitoses was correlated with several clinicopathologic parameters and the myPath score.

Materials and methods

Following Institutional Review Board (IRB) approval, a total of 76 junctional or compound melanocytic lesions previously diagnosed at our institution, were evaluated for the presence of epidermal mitoses. The cases comprised 46 straightforward lesions and 30 challenging lesions (Table 1). The straightforward cases were diagnosed by the primary dermatopathologist on histologic basis only, and included 24 benign dysplastic nevi (16 moderate dysplasia and 8 severe dysplasia) and 22 melanomas (8 *in situ*, 12 superficial spreading melanoma, 1 lentigo maligna melanoma and 1 acral lentiginous melanoma). The challenging cases were diagnosed after expert consensus (JSK, SDB, MTT and AAA) and analysis by melanoma-FISH using

Table 1. Case distribution based on histopathologic interpretation

ALM, acral lentiginous melanoma; AMP, atypical melanocytic proliferation; AST, atypical Spitz tumor; LMM, lentigo maligna melanoma; SSM, superficial spreading melanoma.

Vysis Melanoma FISH Probes (Abbott Molecular, Des Plaines, IL, USA) for 6p25 (*RREB1*), CEP6, 6q23 (*MYB*), 11q13 (*CCND1*), 8q24 (*MYC*), 9p21 (*CDKN2A*) and CEP9 (centromeric reference). The final pathologic interpretation was favor-benign in 12 cases (2 spitzoid, 1 non-dysplastic and 9 dysplastic), ambiguous in 9 cases [6 atypical Spitz tumor (AST), 3 atypical melanocytic proliferation (AMP)] and favor-malignant in 9 cases.

All 46 straightforward cases and 28 of the 30 challenging cases were also characterized with myPath gene expression score (Myriad Genetic Laboratories).

Epidermal melanocytic mitosis were identified and distinguished from keratinocyte mitoses based on the location within a melanocytic nest, the quality of the cytoplasm and the lack of cell adhesion structures. The epidermal mitoses were normalized for the amount of tissue present for evaluation as follows: the total number of epidermal mitoses counted on all levels of all sections available for each lesion was divided by the number of levels and the measured junctional component length in millimeters (mm). The result expressed the density of epidermal mitoses/mm length for each lesion (epidermal mitotic density or EMD).

Other histologic parameters recorded were the Breslow's depth and number of dermal melanocytic mitoses (for melanomas only) and the presence of associated inflammation, either in the form of chronic inflammatory infiltrates involving the melanocytic proliferations or as incidental chronic folliculitis. None of the lesions showed significant acute inflammation.

Statistical comparisons were made between the presence of epidermal mitoses or EMD and multiple clinicopathologic parameters including: patient age and sex, anatomic location of the lesion, histologic diagnosis, presence of inflammation, Breslow's depth (for melanomas only) and myPath score. To derive p values, Fisher's exact test and chi-square test were used for categorical data, whereas Wilcoxon rank sum test and Kruskal-Wallis test were used for measured data.

Results

Epidermal mitoses in straightforward dysplastic nevi and melanomas

Clinicopathologic features and mitotic prevalence

The clinicopathologic characteristics of the 46 straightforward cases are listed in Table S1, Supporting Information and summarized in Table 2.

Table 2. Statistical analysis of clinicopathologic features in the straightforward case group

	Benign Median (range) or N (%)	Malignant Median (range) or N (%)	p
Age	51 (22–91)	61 (20–91)	**0.02**
Sex			
Female	9 (38%)	5 (23%)	
Male	15 (62%)	17 (77%)	0.35
Site			
Arm/leg/foot	11 (46%)	4 (18%)	
Trunk	13 (54%)	13 (59%)	
Head	0	5 (23%)	**0.02**
Inflammation			
No	10 (42%)	7 (32%)	
Yes	14 (58%)	15 (68%)	0.55
Epidermal mitoses (total)	0 (0–5)	1.0 (0–24)	**0.001**
No. levels	6 (1–17)	4 (1–15)	0.27
EMD	0 (0–0.10)	0.04 (0–0.32)	**0.001**
EMD >0.01			
No	19 (**79%**)	5 (23%)	
Yes	5 (21%)	17 (**77%**)	**0.0003**
myPath group			
Benign (<−2.0)	19 (**79%**)	2 (9%)	
Indeterminate (−2.0 to 0)	5 (21%)	4 (18%)	
Malignant (≥0)	0	16 (**73%**)	**<0.0001**

EMD, epidermal mitotic density.

Representative images of a dysplastic nevus and a melanoma with epidermal melanocytic mitoses are shown in Fig. 1. Statistically significant differences in clinical parameters between patients with benign vs. malignant lesions included median age (51 vs. 61, p = 0.02) and frequency lesions on extremities (46% vs. 18%, p = 0.02). There was no significant difference in sex or presence of inflammation (Table 2).

Of 24 benign dysplastic nevi, 6 (25%) nevi (5 moderate dysplasia and 1 severe dysplasia) showed one or more epidermal mitoses (median 2, range 1–5) with a median EMD of 0/mm (range 0–0.10/mm). No dermal mitoses were seen. There was no significant difference in patient age or sex for dysplastic nevi with epidermal mitoses (median age 48.5; M : F = 1 : 1) and nevi without epidermal mitoses (median age 52, p = 0.56; M : F = 2 : 1, p = 0.63). There was also no difference in the anatomic location of the nevi with epidermal mitoses (trunk 3/6, 50%; leg 2/6, 33%; arm 1/6, 17%) and without epidermal mitoses (trunk 10/18, 56%; leg 4/18, 22%; arm 4/18, 22%). Chronic inflammation was present in 4 of 6 (67%) nevi with epidermal mitoses and in 10 of 18 (56%) nevi without mitoses (p = 0.5).

Fig. 1. Representative images of unequivocal benign and malignant lesions with epidermal melanocytic mitoses (arrows): dysplastic nevus (A) ×100, (B) ×400; melanoma (C) ×100, (D) ×400.

Of 22 melanomas, 17 (77%) showed one or more epidermal mitoses (median 2, range 1–24) with a median EMD of 0.04/mm (range 0–0.32/mm), significantly higher than that in benign nevi (p = 0.001) (Fig. 2A). Five melanomas showed no epidermal mitoses (three *in situ*, one LMM and one SSM). Of the 14 invasive melanomas, only 4 had dermal mitoses (median 1.5/mm^2, range 1–5/mm^2), while 12 of 14 had epidermal mitoses (median 0.06/mm, range 0.02–0.32/mm). Interestingly, the EMD (mitoses/mm) showed a good correlation with the Breslow's thickness (mm) for all invasive melanomas (r = 0.79; Fig. 2B). There was no significant difference in patient age for melanomas with epidermal mitoses (median age 59) and melanomas without epidermal mitoses (median age 76; p = 0.37). Although all five melanomas without epidermal mitoses were in men, the sample size was too small for a meaningful comparison. There was also no difference in the anatomic location of melanomas with epidermal mitoses (trunk 9/17, 53%; head/neck 4/17, 23%; arm 2/17, 12%; leg 1/17, 6%; acral 1/17, 6%) and without epidermal mitoses (trunk 4/5, 80%; head 1/5, 20%). Chronic inflammation or folliculitis was present in 12 of 17 (71%) melanomas with epidermal mitoses and in 3 of 5 (60%) melanomas without mitoses (no significant difference, p = 1).

Discriminatory power of epidermal mitoses

By applying a recursive portioning algorithm, an EMD cutoff of 0.01 mitoses/mm was calculated to best separate benign and malignant lesions. With this cutoff, EMD shows a sensitivity of 77% and a specificity of 79% in distinguishing straightforward melanomas from nevi (Fig. 2A, Table 2). Phenotypic characterization by myPath gene expression score was available on all of the cases in this cohort, as a discriminatory standard. Here, the gene expression score was concordant with the histologic diagnosis in 16 of 22 melanomas (73% sensitivity) and 19 of 24 dysplastic nevi (79% specificity) (Table 2). It was indeterminate in 5 of 24 (21%) nevi and 4 of 22 (18%) melanomas and discordant in 2 of 22 (9%) melanomas. The myPath score showed a weak correlation with the Breslow's thickness (r = 0.23) on 14 invasive melanomas. It did not show a significant correlation with the patient age, sex, body site or presence of inflammation. Overall, for the straightforward lesions, EMD (cutoff 0.01) was non-inferior to myPath in distinguishing benign from malignant lesions. When using a combined test approach, where a 'positive' result was considered if either EMD was >0.01 or myPath was positive in any combination with the other test's result, the sensitivity in detecting melanomas increased to 95% with 79% specificity.

Fig. 2. Distribution of epidermal mitotic density (EMD) in straightforward benign and malignant lesions (A) with a cutoff of 0.01/mm (median EMD on top). Correlation between EMD and Breslow's thickness on 14 straightforward invasive melanomas (B) (r_S Spearman non-parametric coefficient).

Epidermal mitoses in challenging/borderline melanocytic proliferations

Clinicopathologic features and mitotic prevalence

The clinicopathologic characteristics of the 30 challenging cases are listed in Table S2 and summarized in Table 3. Representative images of a Spitz nevus and an AST with epidermal melanocytic mitoses are shown in Fig. 3. The sole baseline clinicopathologic feature which differed significantly between the favor-benign, ambiguous and favor-malignant lesions was the presence of inflammation, which was present in increasing proportions with increasing histologic grade (17%, 56%, 89%, respectively; p = 0.004 overall, p = 0.002 between favor-benign and favor-malignant). There was no significant difference in patient age, sex or anatomic location (Table 3). All favor-malignant lesions had molecular confirmation with positive melanoma-FISH, whereas all favor-benign and ambiguous lesions were FISH-negative. FISH results were known to the expert pathologists at the time of consensus diagnosis.

Epidermal mitoses were present in 2 of 12 (17%) favor-benign lesions (1/10 non-Spitz, 1/2 Spitz; median EMD 0/mm, range 0–0.75/mm), 7 of 9 ambiguous lesions (5/6 AST, 2/3 AMP; median EMD 0.11/mm, range 0–1.10/mm) and 6 of 9 (67%) favor-malignant lesions (median EMD 0.04/mm, range 0–0.4/mm) (Fig. 4A). The difference in median EMD between the three groups of lesions was statistically significant (p = 0.03). When isolated as a separate group, Spitz lesions (favor-benign and ambiguous AST) had by far the highest EMD (median 0.14/mm, range 0–1.1/mm) compared with the remaining favor-benign non-Spitz lesions (median 0/mm, range 0–0.11/mm, similar to that seen in the benign straightforward lesions), ambiguous AMP lesions (median 0.04/mm, range 0–0.04/mm) and favor-malignant lesions (median 0.04/mm, range 0–0.4/mm) (Fig. 4B). Dermal mitoses were also present in one of two Spitz nevi and in five of six AST. In comparison, only two of nine (22%) favor-malignant lesions had dermal mitoses (median 2/mm^2). In this group of nine favor-malignant lesions, EMD showed weak correlation with Breslow's thickness (Fig. 4C, r = 0.43) compared with that seen with straightforward melanomas.

Including all 30 challenging lesions, there was no significant difference in patient age or sex between those with epidermal mitoses (mean age 51; M : F = 1 : 1.1) and those without epidermal mitoses (mean age 41, p = 0.24; M : F = 2 : 1, p = 0.46). There was also no difference in the anatomic location of lesions with epidermal mitoses (trunk 9/15, 60%; arm 3/15, 20%; leg 2/15, 13%; head/neck 1/15, 7%) and without epidermal mitoses (trunk 8/15, 53%; leg 4/15, 27%; arm 1/15, 7%; head/neck 1/15, 7%; acral 1/15, 7%) (Table 3).

Discriminatory power of epidermal mitoses

EMD with a cutoff of 0.01/mm showed a sensitivity of 67% and a specificity of 82% in distinguishing the 9 favor-malignant lesions from the 12 favor-benign lesions (Table 3; Fig. 4A). As a comparative standard, myPath gene expression scoring was concordant with the histologic diagnosis in 6 of 9 favor-malignant lesions (67% sensitivity) and 5 of 11 favor-benign lesions (45% specificity) (Table 3). In the ambiguous subgroup of challenging lesions, EMD would label two of nine (22%) as benign (one AST, one AMP) and seven of nine (78%) as malignant (five AST, two AMP)

139

Table 3. Statistical analysis of clinicopathologic features in the challenging case group

|	Favor-benign Median (range) or N (%)	Ambiguous Median (range) or N (%)	Favor-malignant Median (range) or N (%)	p (all groups)	p (benign vs. malignant)
Age	60 (16−80)	33 (5−56)	57 (18−82)	0.16	0.83
Sex					
Female	5 (42%)	6 (67%)	3 (33%)		
Male	7 (58%)	3 (33%)	6 (67%)	0.33	1
Site					
Arm/leg/foot	4 (33%)	4 (44%)	3 (33%)		
Trunk	8 (67%)	3 (33%)	6 (67%)		
Head	0	2 (22%)	0	0.19	1
Inflammation					
No	10 (83%)	4 (44%)	1 (11%)		
Yes	2 (17%)	5 (56%)	8 (89%)	**0.004**	**0.002**
EMD	0 (0−0.75)	0.11 (0−1.10)	0.04 (0−0.40)	**0.03**	0.06
EMD >0.01					
No	10 (**83%**)	2 (22%)	3 (33%)		
Yes	2 (17%)	7 (78%)	6 (**67%**)	**0.01**	**0.03**
myPath group					
Benign (<−2.0)	5 (**45%**)	4 (50%)	3 (33%)		
Indeterminate (−2.0 to 0)	4 (36%)	2 (25%)	0		
Malignant (≥0)	2 (18%)	2 (25%)	6 (**67%**)	0.14	**0.04**

EMD, epidermal mitotic density.

Fig. 3. Representative images of challenging lesions with epidermal melanocytic mitoses (arrows): Spitz nevus (A) ×100, (B) ×400; atypical Spitz tumor (C) ×100, (D) ×400.

based upon the cutoff of 0.01/mm. myPath categorized four of eight (50%) lesions (three AST, one AMP) as benign, two of eight (25%) lesions (one AST, one AMP) as indeterminate and two of eight (25%) lesions (one AST, one AMP) as malignant. For one lesion, the test was technically unsuccessful. While true classification of these cases may be aided by long-term follow up, overall, patients in this category would be expected to have excellent survival given that six of nine cases represent FISH-negative (including 9p21) AST, and the remaining three of nine cases of AMP would have Breslow's thicknesses of (0.3, 0.5 and 0.6 mm). Overall,

Fig. 4. Distribution of epidermal mitotic density (EMD) in challenging favor-benign, ambiguous and favor-malignant lesions (A) with a cutoff of 0.01/mm (median EMD on top). Similar distribution of EMD when Spitzoid lesions (favor-benign and ambiguous) are grouped separately (B). Correlation between EMD and Breslow's thickness on nine invasive favor-malignant lesions (C) (r_S Spearman non-parametric coefficient).

excluding ambiguous lesions, EMD (cutoff 0.01) was again non-inferior to myPath in distinguishing favor-benign from favor-malignant lesions. When using the same combined EMD-myPath test approach as described above, the sensitivity in segregating non-ambiguous lesions increased to 78% with 73% specificity.

Discussion

Despite the repeated investigation of dermal mitoses in benign and malignant melanocytic proliferations,[11,13–17] relatively little information exists in the literature as to the prevalence, frequency and meaning of junctional mitoses in melanocytic lesions. Indeed, in our experience, junctional mitoses may be equally rare in typical banal nevi as compared with dermal mitoses. We inferred that epidermal mitoses may be biologically significant in melanoma and borderline lesions. Because melanomagenesis begins at the dermal-epidermal junction, as manifest by the propensity of radial growth phase to precede vertical growth phase, this histologic sign may be more readily available in borderline cases. Mechanistically, the direct contact of melanoma cells with upper layer keratinocytes resulting from radial growth was shown to instigate molecular interactions that trigger vertical invasion by melanocytes.[18] Indeed, many of the genes recently associated with prognosis in melanoma represent keratinocyte genes, which may allude to an under-recognized importance of the epidermal microenvironment.[19] As such, we hypothesized that the presence and number/density of epidermal mitoses may represent another diagnostic clue in the assessment of borderline melanocytic lesions.

Our findings show that epidermal mitoses are more common and of higher density in straightforward malignant lesions as well as challenging cases that are ultimately designated as malignant compared with those straight away or ultimately classified as benign. This difference in prevalence (77% vs. 25%, p = 0.0012 in straightforward; 67% vs. 17%, p = 0.059 in challenging) and median EMD (0 vs. 0.04, p = 0.001 in straightforward; 0 vs. 0.04, p = 0.06 in challenging) appears to be slightly stronger in straightforward lesions, as would be expected (Tables 2 and 3). Our studies confirm our impression that even *epidermal* mitoses are not found in the majority of even moderately and severely dysplastic *nevi* (75% without EM), where no dermal mitoses were found. In contrast, the majority of melanomas had EM, while only 18%

of melanomas had dermal mitoses, making this histologic feature less useful (albeit more specific). In straightforward nevi and melanomas, the presence of EM did not correlate with any clinical factors, and there was no significant difference in the amount of chronic inflammation in lesions with and without epidermal mitoses. These data suggest that in neoplasms falling on the dysplasia melanoma continuum, EM result from tumor cell autonomous factors rather than external ones.

When looking at the cohort of 30 challenging lesions, even after FISH and myPath studies, 9 of 30 cases were given an expert consensus designation of ambiguous. Of the 21 remaining cases, EM was significantly increased in favor-malignant cases compared with favor-benign as described earlier. Meanwhile, only two of nine (22%) cases ultimately called melanoma had dermal mitoses, rendering this feature less applicable. The baseline clinicopathologic features were comparable in all 30 cases, aside from histologic inflammation that was significantly increased in the ambiguous and favor-malignant lesions, compared with those ultimately called benign (Table 3).

It bears deliberate discussion that Spitz lesions confound the data with the largest number of epidermal and dermal mitoses overall; and, as with every other aspect of their analysis, should be treated as their own entity. Spitz lesions are increasingly proving to represent a genetically and biologically unique group, as manifest by their increased propensity to spread to regional lymph nodes but be otherwise non-lethal for the most part. Indeed, even dermal mitoses have been previously described in non-malignant Spitzoid lesions[7] and were noted in our study as well. Our data support the tradition of allowing dermal mitoses in non-malignant Spitz tumors, and show the same for epidermal mitoses.

While expert histologic diagnosis still remains the gold standard for classifying melanocytic lesions,[20] the interobserver disagreement rate is non-trivial[21−23] and a subset of cases are still interpreted as ambiguous. Thus, objective molecular tests like FISH for melanoma-associated genomic aberrations or myPath gene expression score are being developed to improve diagnostic accuracy. The melanoma-FISH assay is better established,[24] but not perfect. It does not show a 100% correlation with histologic diagnosis, but the pathologist faced with a challenging melanocytic lesion is hard-pressed not to interpret it as melanoma in the presence of a positive FISH result. On the other hand, as the assay covers only select genomic loci, malignancy cannot be excluded with a negative FISH result, but becomes less probably. Concordantly, in our study, all the lesions in the challenging group that were positive by melanoma-FISH were interpreted as favor-malignant. The myPath gene expression score assay also distinguishes between benign and malignant melanocytic lesions with reported sensitivity and specificity comparable with those of FISH.[25] As a difference, myPath has the caveat of an 'indeterminate' result category for a small but significant fraction of cases. Furthermore, our recent work revealed discordant results between the two ancillary tests in a subset of cases, especially challenging lesions, for which unequivocal molecular results would be most needed.[26]

We determined based on the straightforward group of cases that an EMD cutoff of 0.01/mm provides the best separation between benign and malignant lesions, with a sensitivity and specificity non-inferior to the myPath gene expression score. When applying this cutoff to the challenging group of cases, the sensitivity and specificity were only marginally lower than in the straightforward group, and remained non-inferior to the myPath score. While the overlap between the presence or absence of epidermal mitoses and a positive or negative myPath score was not complete, the gene expression score results provides additional validation for the potential discriminatory power of EMD between malignant and benign lesions. It is indeed possible that the myPath test includes a metric of genes expressed during junctional melanocyte proliferation.

In the challenging group, there was an interesting and significant increase in the proportion of cases with inflammation from favor-benign to ambiguous and to favor-malignant lesions (Table 3). Inflammation may be regarded as a response to an aggressive melanocytic proliferation or mutation-associated neoantigen expression. Conversely, it can be argued that inflammation may induce secondary melanocyte activation and proliferation, resulting in increased mitoses, possibly a modified molecular milieu and even skewing of a gene expression-based test like myPath.[26] Our results suggest that in straightforward cases, inflammation is not confounding and does not impact EM, but in borderline lesions inflammation can confound interpretation. The mechanisms by which inflammation influences histologic and molecular melanocytic attributes require further study.

Our results additionally revealed a positive correlation between EMD and Breslow's thickness in invasive melanomas, which was stronger in straightforward lesions. This is not explained simply by the overall size of the lesion, as EMD is independent of lesion breadth, but is more probably related to the biologic potential of the malignancy, where an aggressive tumor has an increased density of epidermal mitoses associated with a deeper dermal infiltration.

Evaluation of melanocytic lesions does not traditionally include an assessment of epidermal mitoses. Here we show that the presence of epidermal mitoses and EMD above 0.01/mm correlate with a diagnosis of malignancy and with the results of a molecular gene expression-based test. While calculating a standard EMD may be viewed as impractical and evaluation for epidermal melanocytic mitoses is not adequate as a single criterion in classifying melanocytic lesions, our study suggests that the presence of more than rare epidermal melanocytic mitoses should be considered as favoring a malignant diagnosis, and should prompt closer investigation for malignancy. Further studies on an expanded cohort with clinical follow-up are warranted to further assess the diagnostic utility and biologic significance of epidermal melanocytic mitoses.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Clinicopathologic characteristics of the 46 straightforward cases in the study cohort.
Table S2. Clinicopathologic characteristics of the 30 challenging cases in the study cohort.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5.
2. Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996; 14: 1218.
3. Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 2010; 62: 751.
4. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996; 27: 528.
5. Hawryluk EB, Sober AJ, Piris A, et al. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol 2012; 67: 727.
6. Gerami P, Busam K, Cochran A, et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol 2014; 38: 934.
7. Harms KL, Lowe L, Fullen DR, Harms PW. Atypical spitz tumors: a diagnostic challenge. Arch Pathol Lab Med 2015; 139: 1263.
8. Urso C, Rongioletti F, Innocenzi D, et al. Histological features used in the diagnosis of melanoma are frequently found in benign melanocytic naevi. J Clin Pathol 2005; 58: 409.
9. http://seer.cancer.gov/statfacts/html/melan.html.
10. LeBoit PE, Massi G. Histological diagnosis of nevi and melanoma, 2nd ed. Berlin, Heidelberg: Springer-Verlag, 2012.
11. O'Rourke EA, Balzer B, Barry CI, Frishberg DP. Nevic mitoses: a review of 1041 cases. Am J Dermatopathol 2013; 35: 30.
12. Tuthill RJ, Reed RJ. Failure of senescence in the dysplasia-melanoma sequence: demonstration using a tissue microarray and a revised paradigm for melanoma. Semin Oncol 2007; 34: 467.
13. Glatz K, Hartmann C, Antic M, Kutzner H. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis. Am J Dermatopathol 2010; 32: 643.
14. Gerami P, Wass A, Mafee M, Fang Y, Pulitzer MP, Busam KJ. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol 2009; 33: 1783.
15. Ruhoy SM, Kolker SE, Murry TC. Mitotic activity within dermal melanocytes of benign melanocytic nevi: a study of 100 cases with clinical follow-up. Am J Dermatopathol 2011; 33: 167.
16. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005; 23: 8048.
17. Litzner BR, Etufugh CN, Stepenaskie S, Hynan LS, Cockerell CJ. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study. Am J Dermatopathol 2012; 34: 827.
18. Golan T, Messer AR, Amitai-Lange A, et al. Interactions of melanoma cells with distal keratinocytes trigger metastasis via notch signaling inhibition of MITF. Mol Cell 2015; 59: 664.
19. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 2015; 21: 175.
20. Tetzlaff MT, Wang WL, Milless TL, et al. Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses. Am J Surg Pathol 2013; 37: 1783.
21. McGinnis KS, Lessin SR, Elder DE, et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 2002; 138: 617.
22. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 2003; 27: 1571.
23. Lodha S, Saggar S, Celebi JT, Silvers DN. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol 2008; 35: 349.
24. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009; 33: 1146.
25. Clarke LE, Warf MB, Flake DD II, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol. 2015; 42: 244.
26. Minca EC, Al-Rohil RN, Wang M, et al. Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. Mod Pathol 2016; 29: 832.